Abstract
Pigment epithelium-derived factor (PEDF) has recently been shown to be the most potent inhibitor of angiogenesis in the mammalian eye, and is involved in the pathogenesis of angiogenic eye disease such as proliferative diabetic retinopathy. However, a functional role for PEDF in tumor growth and angiogenesis remains to be determined. Melanoma is one of the most highly invasive and metastatic tumors. Malignant Melanoma is an increasingly common malignancy and also one the most invasive and metastatic tumors, and its mortality rates have been rapidly increasing above those of any other cancer in recent years. Surgical resection and systemic chemotherapy are the main therapeutic strategies for the treatment of malignant melanoma. However, these approaches are insufficiently effective and may be associated with significant adverse effects. Angiogenesis, a process by which new vascular networks are formed from pre-existing capillaries, is required for tumors to grow, invade and metastasize. Tumor vessels are genetically stable, and less likely to accumulate mutations that allow them to develop drug resistance in a rapid manner. Therefore, targeting vasculatures that support tumor growth, rather than cancer cells, is currently considered the most promising approach to malignant melanoma therapy. Now, novel anti-angiogenic agents with tolerable side effects are actually desired for the treatment of patients with malignant melanoma. In this paper, we review the current understanding of anti-angiogenic therapy for malignant melanoma, especially focusing on PEDF, which was recently identified as the most potent endogenous inhibitor of angiogenesis in the mammalian eye.
Keywords: Angiogenesis, Pigment epithelium-derived factor (PEDF), metastatic tumors, Malignant Melanoma, chemotherapy, cancer cells
Current Pharmaceutical Design
Title: Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition
Volume: 14 Issue: 36
Author(s): Riichiro Abe, Yasuyuki Fujita, Sho-ichi Yamagishi and Hiroshi Shimizu
Affiliation:
Keywords: Angiogenesis, Pigment epithelium-derived factor (PEDF), metastatic tumors, Malignant Melanoma, chemotherapy, cancer cells
Abstract: Pigment epithelium-derived factor (PEDF) has recently been shown to be the most potent inhibitor of angiogenesis in the mammalian eye, and is involved in the pathogenesis of angiogenic eye disease such as proliferative diabetic retinopathy. However, a functional role for PEDF in tumor growth and angiogenesis remains to be determined. Melanoma is one of the most highly invasive and metastatic tumors. Malignant Melanoma is an increasingly common malignancy and also one the most invasive and metastatic tumors, and its mortality rates have been rapidly increasing above those of any other cancer in recent years. Surgical resection and systemic chemotherapy are the main therapeutic strategies for the treatment of malignant melanoma. However, these approaches are insufficiently effective and may be associated with significant adverse effects. Angiogenesis, a process by which new vascular networks are formed from pre-existing capillaries, is required for tumors to grow, invade and metastasize. Tumor vessels are genetically stable, and less likely to accumulate mutations that allow them to develop drug resistance in a rapid manner. Therefore, targeting vasculatures that support tumor growth, rather than cancer cells, is currently considered the most promising approach to malignant melanoma therapy. Now, novel anti-angiogenic agents with tolerable side effects are actually desired for the treatment of patients with malignant melanoma. In this paper, we review the current understanding of anti-angiogenic therapy for malignant melanoma, especially focusing on PEDF, which was recently identified as the most potent endogenous inhibitor of angiogenesis in the mammalian eye.
Export Options
About this article
Cite this article as:
Abe Riichiro, Fujita Yasuyuki, Yamagishi Sho-ichi and Shimizu Hiroshi, Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition, Current Pharmaceutical Design 2008; 14 (36) . https://dx.doi.org/10.2174/138161208786898626
DOI https://dx.doi.org/10.2174/138161208786898626 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry Recent Advances in Nanoparticle Carriers for Coordination Complexes
Current Topics in Medicinal Chemistry Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery MicroRNA Levels in Cervical Cancer Samples and Relationship with Lesion Grade and HPV Infection
MicroRNA Factors Affecting Quantification in PET/CT Imaging
Current Medical Imaging Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice
Current Pharmaceutical Design Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine Vybrant DyeCycle Violet Stain Discriminates Two Different Subsets of CD34+ Cells
Current Stem Cell Research & Therapy Nutritional and Therapeutic Potential of Spirulina
Current Pharmaceutical Biotechnology Diagnostic Usage of Low Dose CT in Solitary Pulmonary Nodule Follow Up in Daily Practice
Current Medical Imaging Interleukin 10 in Antiviral Responses
Current Immunology Reviews (Discontinued) Curcumin: A Natural Lead for Potential New Drug Candidates
Current Medicinal Chemistry Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma
Current Molecular Pharmacology Overview of Prostate Biomarkers as Potential Targets for Immunotherapy
Current Cancer Therapy Reviews α-Halogenoacrylic Derivatives of Antitumor Agents
Mini-Reviews in Medicinal Chemistry Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Current Topics in Medicinal Chemistry